Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 153 articles:
HTML format
Text format



Single Articles


    March 2017
  1. BOONSTRA MC, Van Driel PB, Keereweer S, Prevoo HA, et al
    Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer.
    Oral Oncol. 2017;66:1-8.
    PubMed     Text format     Abstract available


    February 2017
  2. PARK JS, Chang JW, Liu L, Jung SN, et al
    Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017 Feb 17. pii: S1368-8375(17)30028.
    PubMed     Text format     Abstract available


  3. BELL RB, Gough MJ, Seung SK, Jutric Z, et al
    Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].
    Oral Oncol. 2017 Feb 12. pii: S1368-8375(17)30021.
    PubMed     Text format    


  4. CAO W, Liu JN, Liu Z, Wang X, et al
    A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:94-101.
    PubMed     Text format     Abstract available


  5. MASSA ST, Osazuwa-Peters N, Christopher KM, Arnold LD, et al
    Competing causes of death in the head and neck cancer population.
    Oral Oncol. 2017;65:8-15.
    PubMed     Text format     Abstract available


  6. RIEKE K, Schmid KK, Lydiatt W, Houfek J, et al
    Depression and survival in head and neck cancer patients.
    Oral Oncol. 2017;65:76-82.
    PubMed     Text format     Abstract available


  7. KRISHNAN AR, Korrapati A, Zou AE, Qu Y, et al
    Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:68-75.
    PubMed     Text format     Abstract available


  8. O'BRIEN KM, Timmons A, Butow P, Gooberman-Hill R, et al
    Associations between neighbourhood support and financial burden with unmet needs of head and neck cancer survivors.
    Oral Oncol. 2017;65:57-64.
    PubMed     Text format     Abstract available


  9. KAINULAINEN S, Tornwall J, Koivusalo AM, Suominen AL, et al
    Dexamethasone in head and neck cancer patients with microvascular reconstruction: No benefit, more complications.
    Oral Oncol. 2017;65:45-50.
    PubMed     Text format     Abstract available


    January 2017
  10. LUCHINI C, Veronese N
    The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system.
    Oral Oncol. 2017 Jan 9. pii: S1368-8375(16)30279.
    PubMed     Text format    


  11. SWICK AD, Stein AP, McCulloch TM, Hartig GK, et al
    Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
    Oral Oncol. 2017;64:65-72.
    PubMed     Text format     Abstract available


  12. BRAVI F, Polesel J, Garavello W, Serraino D, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and head and neck cancers risk.
    Oral Oncol. 2017;64:59-64.
    PubMed     Text format     Abstract available


  13. VAN DEUDEKOM FJ, Schimberg AS, Kallenberg MH, Slingerland M, et al
    Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review.
    Oral Oncol. 2017;64:27-36.
    PubMed     Text format     Abstract available


  14. LIU YC, Wang WY, Twu CW, Jiang RS, et al
    Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients.
    Oral Oncol. 2017;64:15-21.
    PubMed     Text format     Abstract available


  15. MORONEY LB, Helios J, Ward EC, Crombie J, et al
    Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT+/-concurrent chemotherapy.
    Oral Oncol. 2017;64:1-8.
    PubMed     Text format     Abstract available


    December 2016
  16. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.
    PubMed     Text format    


  17. GALVAO-MOREIRA LV, da Cruz MC
    Corrigendum to "Oral microbiome, periodontitis and risk of head and neck cancer" [Oral Oncol. 53 (2016) 17-19].
    Oral Oncol. 2016 Dec 23. pii: S1368-8375(16)30266.
    PubMed     Text format    


  18. LI YJ, Lai WT, Chang CC, Kuo MY, et al
    Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression.
    Oral Oncol. 2016 Dec 21. pii: S1368-8375(16)30214.
    PubMed     Text format     Abstract available


  19. YAMAMOTO VN, Thylur DS, Bauschard M, Schmale I, et al
    Overcoming radioresistance in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;63:44-51.
    PubMed     Text format     Abstract available


  20. FERNANDEZ-MATEOS J, Seijas-Tamayo R, Mesia R, Taberna M, et al
    Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Oral Oncol. 2016;63:38-43.
    PubMed     Text format     Abstract available


  21. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Text format     Abstract available


  22. PATIL V, Joshi A, Noronha V, Deodhar J, et al
    Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
    Oral Oncol. 2016;63:10-15.
    PubMed     Text format     Abstract available


    November 2016
  23. DASTE A, de Mones E, Digue L, Francois L, et al
    Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
    Oral Oncol. 2016 Nov 3. pii: S1368-8375(16)30196.
    PubMed     Text format    


  24. PENG H, Chen L, Li WF, Zhang Y, et al
    Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis.
    Oral Oncol. 2016;62:78-84.
    PubMed     Text format     Abstract available


  25. LIU L, Chang JW, Jung SN, Park HS, et al
    Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma.
    Oral Oncol. 2016;62:72-77.
    PubMed     Text format     Abstract available


  26. MERMOD M, Tolstonog G, Simon C, Monnier Y, et al
    Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2016;62:60-71.
    PubMed     Text format     Abstract available


  27. DEL BARCO MORILLO E, Mesia R, Adansa Klain JC, Vazquez Fernandez S, et al
    Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
    Oral Oncol. 2016;62:54-59.
    PubMed     Text format     Abstract available


  28. BLANCHARD P, Volk RJ, Ringash J, Peterson SK, et al
    Assessing head and neck cancer patient preferences and expectations: A systematic review.
    Oral Oncol. 2016;62:44-53.
    PubMed     Text format     Abstract available


  29. CHENG SJ, Chang CF, Lee JJ, Chen HM, et al
    Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer.
    Oral Oncol. 2016;62:34-43.
    PubMed     Text format     Abstract available


  30. SWARTZ JE, Pothen AJ, Wegner I, Smid EJ, et al
    Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.
    Oral Oncol. 2016;62:28-33.
    PubMed     Text format     Abstract available


  31. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Text format     Abstract available


  32. KUO TJ, Chu CH, Tang PL, Lai YC, et al
    Effects of geographic area and socioeconomic status in Taiwan on survival rates of head and neck cancer patients after radiotherapy.
    Oral Oncol. 2016;62:136-138.
    PubMed     Text format    


  33. NAIK PP, Das DN, Panda PK, Mukhopadhyay S, et al
    Implications of cancer stem cells in developing therapeutic resistance in oral cancer.
    Oral Oncol. 2016;62:122-135.
    PubMed     Text format     Abstract available


  34. OU D, Blanchard P, El Khoury C, De Felice F, et al
    Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Oral Oncol. 2016;62:114-121.
    PubMed     Text format     Abstract available


  35. LIM YC, Liu L, Chang JW, Koo BS, et al
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis.
    Oral Oncol. 2016;62:109-113.
    PubMed     Text format     Abstract available


  36. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.
    Oral Oncol. 2016;62:1-10.
    PubMed     Text format     Abstract available


    October 2016
  37. EDER-CZEMBIREK C, Czembirek C, Selzer E
    Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival" [Oral Oncol. 60 (2016) 1-7].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30192.
    PubMed     Text format    


  38. LOW GM, Thylur DS, Yamamoto V, Sinha UK, et al
    Erratum to "The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma" [Oral Oncol. 61 (2016) 27-30].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30193.
    PubMed     Text format    


  39. BAXI SS, Dunn LA, Burtness BA
    Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 21. pii: S1368-8375(16)30182.
    PubMed     Text format    


  40. ZOLKIND P, Dunn GP, Lin T, Griffith M, et al
    Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 14. pii: S1368-8375(16)30175.
    PubMed     Text format     Abstract available


  41. MATHIALAGAN A, Verma RK, Panda NK
    Comparison of spinal accessory dysfunction following neck dissection with harmonic scalpel and electrocautery - A randomized study.
    Oral Oncol. 2016;61:142-5.
    PubMed     Text format     Abstract available


  42. ADHAULIYA N, Kalappanavar AN, Ali IM, Annigeri RG, et al
    Autophagy: A boon or bane in oral cancer.
    Oral Oncol. 2016;61:120-6.
    PubMed     Text format     Abstract available


  43. DIVI V, Tao L, Whittemore A, Oakley-Girvan I, et al
    Geographic variation in Medicare treatment costs and outcomes for advanced head and neck cancer.
    Oral Oncol. 2016;61:83-8.
    PubMed     Text format     Abstract available


  44. HAGEDOORN P, Vandenheede H, Vanthomme K, Willaert D, et al
    A cohort study into head and neck cancer mortality in Belgium (2001-11): Are individual socioeconomic differences conditional on area deprivation?
    Oral Oncol. 2016;61:76-82.
    PubMed     Text format     Abstract available


  45. PURKAYASTHA M, McMahon AD, Gibson J, Conway DI, et al
    Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) - A socioeconomic perspective.
    Oral Oncol. 2016;61:70-5.
    PubMed     Text format     Abstract available


  46. CHAMCHOD S, Fuller CD, Mohamed AS, Grossberg A, et al
    Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement.
    Oral Oncol. 2016;61:62-9.
    PubMed     Text format     Abstract available


  47. FIGUEIREDO RA, Weiderpass E, Tajara EH, Strom P, et al
    Diabetes mellitus, metformin and head and neck cancer.
    Oral Oncol. 2016;61:47-54.
    PubMed     Text format     Abstract available


  48. WIRTH LJ, Dakhil S, Kornek G, Axelrod R, et al
    PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;61:31-40.
    PubMed     Text format     Abstract available


  49. LOW GM, Thylur DS, N Yamamoto V, Sinha UK, et al
    The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:27-30.
    PubMed     Text format     Abstract available


  50. SINEVICI N, O'sullivan J
    Oral cancer: Deregulated molecular events and their use as biomarkers.
    Oral Oncol. 2016;61:12-8.
    PubMed     Text format     Abstract available


  51. SCHMIDT H, Kulasinghe A, Kenny L, Punyadeera C, et al
    The development of a liquid biopsy for head and neck cancers.
    Oral Oncol. 2016;61:8-11.
    PubMed     Text format     Abstract available


  52. ADKINS D, Ley J, Michel L, Wildes TM, et al
    nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:1-7.
    PubMed     Text format     Abstract available


    September 2016
  53. RANCOULE C, Vallard A, Espenel S, Guy JB, et al
    Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Oral Oncol. 2016 Sep 9. pii: S1368-8375(16)30154.
    PubMed     Text format     Abstract available


  54. BRYAN BELL R, Gough MJ, Seung SK, Jutric Z, et al
    Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.
    Oral Oncol. 2016 Sep 7. pii: S1368-8375(16)30149.
    PubMed     Text format     Abstract available


  55. MANSHA MA, Abbasi AN, Ali N, Hafiz A, et al
    Correspondence on review article published in Oral Oncology (Vol. 59, August 2016): "Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer."
    Oral Oncol. 2016 Sep 6. pii: S1368-8375(16)30152.
    PubMed     Text format    


  56. LIN Y, Mallen-St Clair J, Wang G, Luo J, et al
    p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;60:81-9.
    PubMed     Text format     Abstract available


  57. LEE JY, Suresh K, Nguyen R, Sapir E, et al
    Predictors of severe long-term toxicity after re-irradiation for head and neck cancer.
    Oral Oncol. 2016;60:32-40.
    PubMed     Text format     Abstract available


  58. MADATHIL SA, Rousseau MC, Wynant W, Schlecht NF, et al
    Nonlinear association between betel quid chewing and oral cancer: Implications for prevention.
    Oral Oncol. 2016;60:25-31.
    PubMed     Text format     Abstract available


  59. LU L, Li J, Zhao C, Xue W, et al
    Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma.
    Oral Oncol. 2016;60:18-24.
    PubMed     Text format     Abstract available


  60. PANDA S, Padhiary SK, Routray S
    Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions.
    Oral Oncol. 2016;60:8-17.
    PubMed     Text format     Abstract available


  61. CHRISTINA EC, Cornelia C, Edgar S
    Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.
    Oral Oncol. 2016;60:1-7.
    PubMed     Text format     Abstract available


    August 2016
  62. DASTE A, de Mones E, Dupin C, Francois L, et al
    m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature.
    Oral Oncol. 2016 Aug 30. pii: S1368-8375(16)30136.
    PubMed     Text format    


  63. SZTURZ P, Faivre S
    Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.
    Oral Oncol. 2016 Aug 28. pii: S1368-8375(16)30135.
    PubMed     Text format    


  64. PAI SI, Zandberg DP, Strome SE
    The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
    Oral Oncol. 2016 Aug 5. pii: S1368-8375(16)30119.
    PubMed     Text format     Abstract available


  65. LICITRA L, Keilholz U, Tahara M, Lin JC, et al
    Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.
    Oral Oncol. 2016;59:73-9.
    PubMed     Text format     Abstract available


  66. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
    Oral Oncol. 2016;59:67-72.
    PubMed     Text format     Abstract available


  67. NOHATA N, Abba MC, Gutkind JS
    Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.
    Oral Oncol. 2016;59:58-66.
    PubMed     Text format     Abstract available


  68. OU D, Levy A, Blanchard P, Nguyen F, et al
    Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Oral Oncol. 2016;59:50-7.
    PubMed     Text format     Abstract available


  69. OOSTING SF, Chen TW, Huang SH, Wang L, et al
    A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.
    Oral Oncol. 2016;59:43-9.
    PubMed     Text format     Abstract available


  70. PRINCE ME, Zhou L, Moyer JS, Tao H, et al
    Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro.
    Oral Oncol. 2016;59:30-42.
    PubMed     Text format     Abstract available


    July 2016
  71. TERENZI V, Cassoni A, Della Monaca M, Priore P, et al
    Oral cancer during pregnancy.
    Oral Oncol. 2016 Jul 2. pii: S1368-8375(16)30092.
    PubMed     Text format    


  72. MICHEL L, Ley J, Wildes TM, Schaffer A, et al
    Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:41-8.
    PubMed     Text format     Abstract available


  73. WANG K, Amdur RJ, Mendenhall WM, Green R, et al
    Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
    Oral Oncol. 2016;58:21-6.
    PubMed     Text format     Abstract available


  74. SUROV A, Stumpp P, Meyer HJ, Gawlitza M, et al
    Simultaneous (18)F-FDG-PET/MRI: Associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:14-20.
    PubMed     Text format     Abstract available


    June 2016
  75. SZTURZ P, Raymond E, Faivre S
    c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.
    Oral Oncol. 2016 Jun 11. pii: S1368-8375(16)30063.
    PubMed     Text format    


  76. KUO TJ, Ko WT, Chang YC, Lai YC, et al
    Risk of osteoradionecrosis in head and neck cancers: Comparison between oral and non-oral cancers.
    Oral Oncol. 2016 Jun 10. pii: S1368-8375(16)30064.
    PubMed     Text format    


  77. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
    Oral Oncol. 2016;57:40-5.
    PubMed     Text format     Abstract available


  78. IQBAL H, Pan Q
    Image guided surgery in the management of head and neck cancer.
    Oral Oncol. 2016;57:32-9.
    PubMed     Text format     Abstract available


  79. RANSOHOFF A, Wood D, Solomon Henry A, Divi V, et al
    Third party assessment of resection margin status in head and neck cancer.
    Oral Oncol. 2016;57:27-31.
    PubMed     Text format     Abstract available


  80. WARD MC, Adelstein DJ, Bhateja P, Nwizu TI, et al
    Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11.
    Oral Oncol. 2016;57:21-6.
    PubMed     Text format     Abstract available


    May 2016
  81. T PARSONS J, D Greene B
    Induction chemotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 May 30. pii: S1368-8375(16)30052.
    PubMed     Text format    


  82. UPPALURI R, Bell RB, Sunwoo JB
    Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches.
    Oral Oncol. 2016 May 26. pii: S1368-8375(16)30050.
    PubMed     Text format    


  83. DAVIS RJ, Van Waes C, Allen CT
    Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
    Oral Oncol. 2016 May 20. pii: S1368-8375(16)30045.
    PubMed     Text format     Abstract available


  84. HASSONA Y, Abu Ghosh M, Abu Ghlassi T, Scully C, et al
    Public engagement with oral cancer on Facebook.
    Oral Oncol. 2016 May 6. pii: S1368-8375(16)30034.
    PubMed     Text format    


  85. TEPPER SR, Zuo Z, Khattri A, Hess J, et al
    Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:62-70.
    PubMed     Text format     Abstract available


  86. OOFT ML, van Ipenburg J, Braunius WW, Stegeman I, et al
    A nation-wide epidemiological study on the risk of developing second malignancies in patients with different histological subtypes of nasopharyngeal carcinoma.
    Oral Oncol. 2016;56:40-6.
    PubMed     Text format     Abstract available


  87. DATTA J, Islam M, Dutta S, Roy S, et al
    Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
    Oral Oncol. 2016;56:32-9.
    PubMed     Text format     Abstract available


  88. LAROCCA CJ, Han J, Salzwedel AO, Davydova J, et al
    Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:25-31.
    PubMed     Text format     Abstract available


  89. DA SILVA JM, Soave DF, Moreira Dos Santos TP, Batista AC, et al
    Significance of chemokine and chemokine receptors in head and neck squamous cell carcinoma: A critical review.
    Oral Oncol. 2016;56:8-16.
    PubMed     Text format     Abstract available


  90. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Text format     Abstract available


  91. SHARMA S, Bekelman J, Lin A, Lukens JN, et al
    Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;56:17-24.
    PubMed     Text format     Abstract available


  92. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Text format     Abstract available


    April 2016
  93. ABBOTT D, Cohen E, Sadeghi N, Stein K, et al
    Considering the survivorship care needs of head and neck cancer survivors.
    Oral Oncol. 2016 Apr 26. pii: S1368-8375(16)30032.
    PubMed     Text format    


  94. ETTL T, El-Gindi A, Hautmann M, Gosau M, et al
    Positive frozen section margins predict local recurrence in R0-resected squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;55:17-23.
    PubMed     Text format     Abstract available


  95. PIERCE CAMPBELL CM, Giuliano AR, Torres BN, O'Keefe MT, et al
    Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.
    Oral Oncol. 2016;55:1-5.
    PubMed     Text format     Abstract available


  96. ROOPER LM, Gandhi M, Bishop JA, Westra WH, et al
    RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.
    Oral Oncol. 2016;55:11-6.
    PubMed     Text format     Abstract available


  97. POLEDNAK AP
    Evidence for a stabilization of incidence rates for base of tongue and tonsil carcinoma in the U.S. white population.
    Oral Oncol. 2016;55:e5-6.
    PubMed     Text format    


  98. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.
    PubMed     Text format    


    March 2016
  99. PATIL VM, Joshi A, Noronha V, Karpe A, et al
    Technically unresectable recurrent oral cancers: Is NACT the answer?
    Oral Oncol. 2016 Mar 31. pii: S1368-8375(16)30008.
    PubMed     Text format    


  100. HU X, Zhang Q, Hua H, Chen F, et al
    Changes in the salivary microbiota of oral leukoplakia and oral cancer.
    Oral Oncol. 2016 Mar 26. pii: S1368-8375(16)00052.
    PubMed     Text format    


  101. TRZASKOWSKA-KOMON E, Wasiak M, Rolinski J, Klatka J, et al
    Dendritic cells generated from peripheral blood monocytes (Mo-DCs) and stimulated with laryngeal cancer cell lysates are not good enough in stimulating anti-tumor immunity.
    Oral Oncol. 2016 Mar 7. pii: S1368-8375(16)00036.
    PubMed     Text format    


  102. DE FELICE F, Musio D, Tombolini V
    Intra-operative radiation therapy (IORT) in recurrent head and neck cancer.
    Oral Oncol. 2016 Mar 3. pii: S1368-8375(16)00042.
    PubMed     Text format    


  103. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Text format     Abstract available


  104. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Text format     Abstract available


  105. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.
    PubMed     Text format    


    February 2016
  106. KRAAIJENGA SA, Oskam IM, van Son RJ, Hamming-Vrieze O, et al
    Assessment of voice, speech, and related quality of life in advanced head and neck cancer patients 10-years+ after chemoradiotherapy.
    Oral Oncol. 2016 Feb 10. pii: S1368-8375(16)00019.
    PubMed     Text format     Abstract available


  107. FIRMINO N, Martinez VD, Rowbotham DA, Enfield KS, et al
    HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer.
    Oral Oncol. 2016 Feb 4. pii: S1368-8375(16)00015.
    PubMed     Text format     Abstract available


  108. SONIS ST, Hashemi S, Epstein JB, Nair RG, et al
    Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients.
    Oral Oncol. 2016 Feb 3. pii: S1368-8375(16)00008.
    PubMed     Text format     Abstract available


  109. SARODE GS, Sarode SC
    Superficial mucoceles at surgical mucosal margins of excised oral cancer specimens: An unexpected finding.
    Oral Oncol. 2016 Feb 2. pii: S1368-8375(16)00005.
    PubMed     Text format    


  110. HUANG YC, Lee YC, Tseng PH, Chen TC, et al
    Regular screening of esophageal cancer for 248 newly diagnosed hypopharyngeal squamous cell carcinoma by unsedated transnasal esophagogastroduodenoscopy.
    Oral Oncol. 2016 Feb 1. pii: S1368-8375(16)00011.
    PubMed     Text format     Abstract available


  111. YIN ZZ, Gao L, Luo JW, Yi JL, et al
    Long-term outcomes of patients with esthesioneuroblastomas: A cohort from a single institution.
    Oral Oncol. 2016;53:48-53.
    PubMed     Text format     Abstract available


  112. KHAN Z, Epstein JB, Marur S, Gillespie MB, et al
    Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.
    Oral Oncol. 2016;53:60-6.
    PubMed     Text format     Abstract available


    January 2016
  113. DEL FABBRO M, Marcazzan S, D'Antico S, Weinstein RL, et al
    Autologous platelet concentrates in head and neck cancer surgery: Are such bio-adjuvants really safe?
    Oral Oncol. 2016 Jan 25. pii: S1368-8375(16)00012.
    PubMed     Text format    


  114. WALL LR, Cartmill B, Ward EC, Hill AJ, et al
    "ScreenIT": Computerized screening of swallowing, nutrition and distress in head and neck cancer patients during (chemo)radiotherapy.
    Oral Oncol. 2016 Jan 20. pii: S1368-8375(16)00007.
    PubMed     Text format     Abstract available


  115. SHIMANE T, Aizawa H, Koike T, Kamiya M, et al
    Oral cancer intraoperative detection by topically spraying a gamma-glutamyl transpeptidase-activated fluorescent probe.
    Oral Oncol. 2016 Jan 19. pii: S1368-8375(15)00429.
    PubMed     Text format    


  116. ANAND R, Sarode GS, Sarode SC
    Chronic stress and oral cancer research: Disregarded aspects in animal model studies.
    Oral Oncol. 2016 Jan 18. pii: S1368-8375(16)00006.
    PubMed     Text format    


  117. BERGAMINI C, Locati L, Bossi P, Granata R, et al
    Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?
    Oral Oncol. 2016 Jan 13. pii: S1368-8375(16)00002.
    PubMed     Text format     Abstract available


  118. MAZUREK AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, et al
    Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Oral Oncol. 2016 Jan 11. pii: S1368-8375(15)00428.
    PubMed     Text format     Abstract available


  119. COSWAY B, Lovat P
    The role of autophagy in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016 Jan 7. pii: S1368-8375(15)00433.
    PubMed     Text format     Abstract available


  120. SAMUELS SE, Tao Y, Lyden T, Haxer M, et al
    Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Oral Oncol. 2016 Jan 5. pii: S1368-8375(15)00416.
    PubMed     Text format     Abstract available


  121. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Text format     Abstract available


  122. VAN MONSJOU HS, Schaapveld M, Hamming-Vrieze O, de Boer JP, et al
    Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study.
    Oral Oncol. 2016;52:37-44.
    PubMed     Text format     Abstract available


    December 2015
  123. GEIGER JL, Grandis JR, Bauman JE
    The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
    Oral Oncol. 2015 Dec 27. pii: S1368-8375(15)00412.
    PubMed     Text format     Abstract available


  124. AHN MJ, D'Cruz A, Vermorken JB, Chen JP, et al
    Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.
    Oral Oncol. 2015 Dec 19. pii: S1368-8375(15)00397.
    PubMed     Text format     Abstract available


  125. WOODY NM, Koyfman SA, Xia P, Yu N, et al
    Regional control is preserved after dose de-escalated radiotherapy to involved lymph nodes in HPV positive oropharyngeal cancer.
    Oral Oncol. 2015 Dec 17. pii: S1368-8375(15)00370.
    PubMed     Text format     Abstract available


  126. BOWLES DW, Keysar SB, Eagles JR, Wang G, et al
    A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2015 Dec 15. pii: S1368-8375(15)00392.
    PubMed     Text format     Abstract available


  127. CHUNG CH, Rudek MA, Kang H, Marur S, et al
    A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Oral Oncol. 2015 Dec 15. pii: S1368-8375(15)00398.
    PubMed     Text format     Abstract available


  128. GALVAO-MOREIRA LV, da Cruz MC
    Oral microbiome, periodontitis and risk of head and neck cancer.
    Oral Oncol. 2015 Dec 10. pii: S1368-8375(15)00391.
    PubMed     Text format     Abstract available


  129. LEE MS, Nelson AM, Thompson LM, Donovan KA, et al
    Supportive care needs of oral cancer survivors: Prevalence and correlates.
    Oral Oncol. 2015 Dec 9. pii: S1368-8375(15)00385.
    PubMed     Text format     Abstract available


  130. SETTON J, Han J, Kannarunimit D, Wuu YR, et al
    Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma.
    Oral Oncol. 2015 Dec 7. pii: S1368-8375(15)00393.
    PubMed     Text format     Abstract available


    November 2015
  131. VAN DER LINDEN N, Flach GB, de Bree R, Uyl-de Groot CA, et al
    Cost-utility of sentinel lymph node biopsy in cT1-T2N0 oral cancer.
    Oral Oncol. 2015 Nov 26. pii: S1368-8375(15)00389.
    PubMed     Text format     Abstract available


  132. BELL RB, Leidner RS, Crittenden MR, Curti BD, et al
    OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.
    Oral Oncol. 2015 Nov 21. pii: S1368-8375(15)00387.
    PubMed     Text format     Abstract available


  133. CHANG JW, Gwak SY, Shim GA, Liu L, et al
    EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Oral Oncol. 2015 Nov 18. pii: S1368-8375(15)00368.
    PubMed     Text format     Abstract available


  134. RYLANDS J, Lowe D, Rogers SN
    Outcomes by area of residence deprivation in a cohort of oral cancer patients: Survival, health-related quality of life, and place of death.
    Oral Oncol. 2015 Nov 12. pii: S1368-8375(15)00361.
    PubMed     Text format     Abstract available


  135. LICITRA L, Mesia R, Keilholz U
    Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2015 Nov 11. pii: S1368-8375(15)00364.
    PubMed     Text format     Abstract available


  136. PEDERSEN A, Wilson J, McColl E, Carding P, et al
    Swallowing outcome measures in head and neck cancer - How do they compare?
    Oral Oncol. 2015 Nov 9. pii: S1368-8375(15)00359.
    PubMed     Text format     Abstract available


  137. LANGIUS JA, Twisk J, Kampman M, Doornaert P, et al
    Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo)radiotherapy.
    Oral Oncol. 2015 Nov 9. pii: S1368-8375(15)00365.
    PubMed     Text format     Abstract available


  138. ANTUNES HS, Schluckebier LF, Herchenhorn D, Small IA, et al
    Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation.
    Oral Oncol. 2015 Nov 7. pii: S1368-8375(15)00366.
    PubMed     Text format     Abstract available


  139. WEI J, Pei S, Zhu X
    Comparison of (18)F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis.
    Oral Oncol. 2015 Nov 4. pii: S1368-8375(15)00354.
    PubMed     Text format     Abstract available


  140. GALVAO-MOREIRA LV, da Cruz MC
    Dental demineralization, radiation caries and oral microbiota in patients with head and neck cancer.
    Oral Oncol. 2015 Nov 2. pii: S1368-8375(15)00352.
    PubMed     Text format    


    October 2015
  141. LI S, Lee YA, Li Q, Chen CJ, et al
    Oral lesions, chronic diseases and the risk of head and neck cancer.
    Oral Oncol. 2015 Oct 29. pii: S1368-8375(15)00358.
    PubMed     Text format     Abstract available


  142. TAKES RP, Wierzbicka M, D'Souza G, Jackowska J, et al
    HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?
    Oral Oncol. 2015 Oct 28. pii: S1368-8375(15)00355.
    PubMed     Text format     Abstract available


  143. LEE YS, Park JY, Cho KJ, Kim SB, et al
    Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer.
    Oral Oncol. 2015 Oct 13. pii: S1368-8375(15)00331.
    PubMed     Text format     Abstract available


    September 2015
  144. RAMQVIST T, Mints M, Tertipis N, Nasman A, et al
    Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters.
    Oral Oncol. 2015 Sep 25. pii: S1368-8375(15)00327.
    PubMed     Text format     Abstract available


    August 2015
  145. AL TAMIMI AS, Zaheer S, Ng DC, Osmany S, et al
    The incidence and sites of Nasopharyngeal carcinoma (NPC) metastases on FDG PET/CT scans.
    Oral Oncol. 2015 Aug 24. pii: S1368-8375(15)00291.
    PubMed     Text format     Abstract available


  146. ZHANG B, Mo Z, Du W, Wang Y, et al
    Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2015 Aug 18. pii: S1368-8375(15)00295.
    PubMed     Text format     Abstract available


    July 2015
  147. LIU SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, et al
    Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.
    Oral Oncol. 2015 Jul 13. pii: S1368-8375(15)00263.
    PubMed     Text format     Abstract available


    June 2015
  148. DAHLSTROM KR, Bell D, Hanby D, Li G, et al
    Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior.
    Oral Oncol. 2015 Jun 25. pii: S1368-8375(15)00239.
    PubMed     Text format     Abstract available


  149. ANDERSON KS, Gerber JE, D'Souza G, Pai SI, et al
    Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.
    Oral Oncol. 2015 Jun 18. pii: S1368-8375(15)00229.
    PubMed     Text format     Abstract available


  150. DAN TD, Raben D, Schneider CJ, Hockstein NG, et al
    Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach.
    Oral Oncol. 2015;51:616-21.
    PubMed     Text format     Abstract available


    May 2015
  151. ANDERSON KS, Dahlstrom KR, Cheng JN, Alam R, et al
    HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
    Oral Oncol. 2015 May 6. pii: S1368-8375(15)00186.
    PubMed     Text format     Abstract available


  152. SINHA P, Kallogjeri D, Gay H, Thorstad WL, et al
    High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer.
    Oral Oncol. 2015;51:514-20.
    PubMed     Text format     Abstract available


    February 2015
  153. TANG C, Fuller CD, Garden AS, Awan MJ, et al
    Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
    Oral Oncol. 2015;51:195-201.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: